Update (4:40 p.m.): Updated with Friday closing price.

NEW YORK (TheStreet) -- Tekmira Pharmaceuticals  (TKMR soared Friday after the company announced Thursday afternoon the Food & Drug Administration had loosened its clinical hold on the company's developmental ebola drug, TKM-Ebola.

The company announced it had received a verbal commitment from the FDA to ease its hold from a full clinical hold to a partial clinical hold, which "enables the potential use of TKM-Ebola in individuals infected with Ebola virus," according to the Tekmira's statement.

The stock closed up 45.06% to $20.70. More than 28 million shares had changed hands, compared to the average volume of 612,942.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TKMR Chart TKMR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.